In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab plus cilgavimab reduced COVID-19

ANNALS OF INTERNAL MEDICINE（2022）

引用 0|浏览0

暂无评分

摘要

Source Citation Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386:2188-200. 35443106 Clinical Impact Ratings Infectious Disease:

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要